A post-hoc analysis of the negative symptom factor score in a proof-of-concept study of glycine reuptake inhibitor bitopertin in schizophrenia

被引：4
|
作者：
Umbricht, D. [1 ]
Lentz, E. [2 ]
Santarelli, L. [3 ]
Lalonde, J. [4 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] Genentech Inc, Biometr, San Francisco, CA 94080 USA
[3] F Hoffmann La Roche Ltd, Neurosci, Basel, Switzerland
[4] F Hoffmann La Roche Ltd, Div Pharmaceut, Basel, Switzerland
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70475-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S311 / S311
页数：1
相关论文
共 50 条
  • [1] A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA
    Umbricht, Daniel
    Lentz, Ellen L.
    Santarelli, Luca
    Lalonde, Justine
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S360 - S360
  • [2] Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
    Umbricht, Daniel
    Alberati, Daniela
    Martin-Facklam, Meret
    Borroni, Edilio
    Youssef, Eriene A.
    Ostland, Michael
    Wallace, Tanya L.
    Knoflach, Frederic
    Dorflinger, Ernest
    Wettstein, Joseph G.
    Bausch, Alexander
    Garibaldi, George
    Santarelli, Luca
    JAMA PSYCHIATRY, 2014, 71 (06) : 637 - 646
  • [3] Impact of improving negative symptoms on functioning in patients with schizophrenia: a post-hoc analysis of a proof-of-concept study
    Blaettler, T.
    Edgar, C.
    Garibaldi, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S310 - S310
  • [4] Glycine reuptake inhibitor bitopertin: characterisation in relation to symptom domains in schizophrenia
    Alberati, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S147 - S147
  • [5] Glycine reuptake inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia
    Umbricht, D.
    Martin-Facklam, M.
    Youssef, E.
    Yoo, K.
    Dorflinger, E.
    Bausch, A.
    Alberati, D.
    Santarelli, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S517 - S518
  • [6] The Effect of Instability of Baseline Severity of Positive Symptoms on End of Treatment Change in the PANSS Negative Factor Score in Negative Symptom Schizophrenia Studies - An Exploratory Post-Hoc Analysis
    Daniel, David
    Wang, Xingmei
    Kott, Alan
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 371 - 371
  • [7] The use of mean circulatory filling pressure analogue for monitoring hemodynamic coherence: A post-hoc analysis of the SPARSE data and proof-of-concept study
    Laou, Eleni
    Papagiannakis, Nikolaos
    Sarchosi, Smaragdi
    Kleisiaris, Konstantinos
    Apostolopoulou, Aggeliki
    Syngelou, Vasiliki
    Kakagianni, Maria
    Christopoulos, Agamemnon
    Ntalarizou, Nicoleta
    Chalkias, Athanasios
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2023, 84 (01) : 19 - 32
  • [8] GLYCINE TRANSPORTER TYPE 1 (GLYT1) INHIBITOR RG1678: RESULTS OF THE PROOF-OF-CONCEPT STUDY FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
    Umbricht, Daniel
    Martin-Facklam, M.
    Pizzagalli, F.
    Youssef, E.
    Yoo, K.
    Dorflinger, E.
    Bausch, A.
    Arrowsmith, R.
    Alberati, D.
    Santarelli, L.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 324 - 324
  • [9] Post-hoc standardisation of parametric T1 maps in cardiovascular magnetic resonance imaging: a proof-of-concept
    Viezzer, Darian
    Hadler, Thomas
    Groeschel, Jan
    Ammann, Clemens
    Blaszczyk, Edyta
    Kolbitsch, Christoph
    Hufnagel, Simone
    Kranzusch-Gross, Riccardo
    Lange, Steffen
    Schulz-Menger, Jeanette
    EBIOMEDICINE, 2024, 102
  • [10] Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study
    Maruyama, Hidenori
    Sano, Fumiya
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Miura, Itaru
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2024, 20 : 1453 - 1463
12345